FMS vs. ACONW, AONC, DHACW, LFMDP, OTRKP, PIIIW, TALKW, TOIIW, NTRA, and HIMS
Should you be buying Fresenius Medical Care AG & Co. KGaA stock or one of its competitors? The main competitors of Fresenius Medical Care AG & Co. KGaA include Aclarion (ACONW), American Oncology Network (AONC), Digital Health Acquisition (DHACW), LifeMD (LFMDP), Ontrak (OTRKP), P3 Health Partners (PIIIW), Talkspace (TALKW), Oncology Institute (TOIIW), Natera (NTRA), and Hims & Hers Health (HIMS). These companies are all part of the "healthcare" industry.
Fresenius Medical Care AG & Co. KGaA vs. Its Competitors
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Aclarion (NASDAQ:ACONW) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.
In the previous week, Fresenius Medical Care AG & Co. KGaA had 1 more articles in the media than Aclarion. MarketBeat recorded 1 mentions for Fresenius Medical Care AG & Co. KGaA and 0 mentions for Aclarion. Aclarion's average media sentiment score of 1.89 beat Fresenius Medical Care AG & Co. KGaA's score of 0.00 indicating that Aclarion is being referred to more favorably in the news media.
Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Aclarion.
8.4% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Fresenius Medical Care AG & Co. KGaA currently has a consensus price target of $27.80, suggesting a potential upside of 4.71%. Given Fresenius Medical Care AG & Co. KGaA's stronger consensus rating and higher probable upside, equities research analysts plainly believe Fresenius Medical Care AG & Co. KGaA is more favorable than Aclarion.
Fresenius Medical Care AG & Co. KGaA has a net margin of 3.18% compared to Aclarion's net margin of 0.00%. Fresenius Medical Care AG & Co. KGaA's return on equity of 6.25% beat Aclarion's return on equity.
Summary
Fresenius Medical Care AG & Co. KGaA beats Aclarion on 9 of the 10 factors compared between the two stocks.
Get Fresenius Medical Care AG & Co. KGaA News Delivered to You Automatically
Sign up to receive the latest news and ratings for FMS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fresenius Medical Care AG & Co. KGaA Competitors List
Related Companies and Tools
This page (NYSE:FMS) was last updated on 7/18/2025 by MarketBeat.com Staff
